| scholarly article | Q13442814 |
| P356 | DOI | 10.1200/JCO.2005.14.415 |
| P698 | PubMed publication ID | 16009947 |
| P50 | author | Alex A Adjei | Q107055463 |
| Lorelei J Hanson | Q107068848 | ||
| Joel M Reid | Q116795055 | ||
| Laura M Bruzek | Q117264212 | ||
| Jill Piens | Q117264214 | ||
| Patricia M. Lorusso | Q117264223 | ||
| P2093 | author name string | Shirish Gadgeel | |
| Mark B Meyer | |||
| Judith Sebolt-Leopold | |||
| Roman Herrera | |||
| David Y Mitchell | |||
| Keri Van Becelaere | |||
| Pamela DeLuca | |||
| Mary Varterasian | |||
| Peggy Asbury | |||
| P433 | issue | 23 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | patient | Q181600 |
| pharmacodynamics | Q725307 | ||
| P304 | page(s) | 5281-5293 | |
| P577 | publication date | 2005-07-11 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies | |
| P478 | volume | 23 |
| Q51636999 | A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors. |
| Q50483589 | A phase I dose-finding, safety and tolerability study of AZD8330 in patients with advanced malignancies |
| Q35563528 | A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors |
| Q52900022 | A potent therapeutics for gallbladder cancer by combinatorial inhibition of the MAPK and mTOR signaling networks |
| Q47735303 | Advances in Molecular Profiling and Categorisation of Pancreatic Adenocarcinoma and the Implications for Therapy. |
| Q38091649 | Advances in personalized targeted treatment of metastatic melanoma and non-invasive tumor monitoring |
| Q37489942 | Advances in preclinical small molecules for the treatment of NSCLC. |
| Q37495626 | Advances in the treatment of pancreatic cancer: limitations of surgery and evaluation of new therapeutic strategies |
| Q38817910 | Allosteric modulators of MEK1: drug design and discovery |
| Q40170177 | An inhibitory effect on cell proliferation by blockage of the MAPK/estrogen receptor/MDM2 signal pathway in gynecologic cancer |
| Q28469210 | Anthrax toxins induce shock in rats by depressed cardiac ventricular function |
| Q37605160 | Apoptosis and autophagy: BIM as a mediator of tumour cell death in response to oncogene-targeted therapeutics |
| Q43422757 | Association of molecular alterations, including BRAF, with biology and outcome in pilocytic astrocytomas |
| Q37772444 | BRAF, a target in melanoma: implications for solid tumor drug development |
| Q37242685 | Biologic therapies for advanced pancreatic cancer |
| Q39365692 | Bridging the Gap between Preclinical and Clinical Studies Using Pharmacokinetic–Pharmacodynamic Modeling: An Analysis of GDC-0973, a MEK Inhibitor |
| Q36813976 | CInQ-03, a novel allosteric MEK inhibitor, suppresses cancer growth in vitro and in vivo |
| Q41829703 | Caveolin-1 deficiency induces a MEK-ERK1/2-Snail-1-dependent epithelial-mesenchymal transition and fibrosis during peritoneal dialysis |
| Q39106999 | Combined effects of PI3K and SRC kinase inhibitors with imatinib on intracellular calcium levels, autophagy, and apoptosis in CML-PBL cells. |
| Q35161368 | Concurrent Targeting of KRAS and AKT by MiR-4689 Is a Novel Treatment Against Mutant KRAS Colorectal Cancer |
| Q42363492 | Constitutive MEK1 Activation Rescues Anthrax Lethal Toxin-Induced Vascular Effects In Vivo |
| Q35951620 | Cotargeting MAPK and PI3K Signaling with Concurrent Radiotherapy as a Strategy for the Treatment of Pancreatic Cancer |
| Q36580838 | Current strategies in overcoming resistance of cancer cells to apoptosis melanoma as a model. |
| Q38005994 | Cutaneous side effects of inhibitors of the RAS/RAF/MEK/ERK signalling pathway and their management |
| Q37803366 | Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886). |
| Q27666709 | Design and synthesis of novel allosteric MEK inhibitor CH4987655 as an orally available anticancer agent |
| Q64263114 | Design, synthesis, and anticancer evaluation of novel quinoline derivatives of ursolic acid with hydrazide, oxadiazole, and thiadiazole moieties as potent MEK inhibitors |
| Q40142110 | Development and validation of a phosphorylated SMAD ex vivo stimulation assay |
| Q37929419 | Development of Novel Targeted Agents in the Treatment of Metastatic Colorectal Cancer |
| Q38100551 | Development of cellular signaling pathway inhibitors as new antivirals against influenza |
| Q35612549 | Disentangling the Complexity of HGF Signaling by Combining Qualitative and Quantitative Modeling |
| Q39842295 | Distinct genetic alterations in the mitogen-activated protein kinase pathway dictate sensitivity of thyroid cancer cells to mitogen-activated protein kinase kinase 1/2 inhibition |
| Q36822438 | Downstream intracellular effectors of epidermal growth factor receptor as targets for anticancer therapy |
| Q26781362 | Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers |
| Q37790671 | EGFR and KRAS in colorectal cancer |
| Q53627379 | ERK1/2 promoted proliferation and inhibited apoptosis of human cervical cancer cells and regulated the expression of c-Fos and c-Jun proteins |
| Q39971699 | Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma |
| Q36866617 | Emerging drugs for the treatment of pancreatic cancer |
| Q41367801 | Enhancing NK cell-mediated cytotoxicity to cisplatin-resistant lung cancer cells via MEK/Erk signaling inhibition |
| Q38120749 | Evolving Pharmacotherapies for the Treatment of Metastatic Melanoma |
| Q36864736 | Evolving approaches to patients with advanced differentiated thyroid cancer |
| Q57044361 | Exploring major signaling cascades in melanomagenesis: a rationale route for targetted skin cancer therapy |
| Q28252845 | Factors underlying sensitivity of cancers to small-molecule kinase inhibitors |
| Q33698374 | From basic research to clinical development of MEK1/2 inhibitors for cancer therapy |
| Q39606314 | GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition |
| Q21129230 | Genetic determinants and potential therapeutic targets for pancreatic adenocarcinoma |
| Q26781443 | Genomic alterations in pancreatic cancer and their relevance to therapy |
| Q36871512 | Gestational trophoblastic neoplasia--pathogenesis and potential therapeutic targets |
| Q54484191 | Hepatocyte growth factor in the neighborhood reverses resistance to BRAF inhibitor in melanoma. |
| Q38007145 | Highlights in antiviral drug research: antivirals at the horizon |
| Q37259707 | Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2. |
| Q38758152 | IFNs-signaling effects on lung cancer: an up-to-date pathways-specific review. |
| Q34129528 | Identification of common predictive markers of in vitro response to the Mek inhibitor selumetinib (AZD6244; ARRY-142886) in human breast cancer and non-small cell lung cancer cell lines |
| Q39336729 | Impact of oncogenic driver mutations on feedback between the PI3K and MEK pathways in cancer cells |
| Q39802740 | Impaired PTPN13 phosphatase activity in spontaneous or HPV-induced squamous cell carcinomas potentiates oncogene signaling through the MAP kinase pathway |
| Q38088281 | In vitro three-dimensional tumor microenvironment models for anticancer drug discovery. |
| Q37118264 | Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas |
| Q35790612 | Inhibiting ERK Activation with CI-1040 Leads to Compensatory Upregulation of Alternate MAPKs and Plasminogen Activator Inhibitor-1 following Subtotal Nephrectomy with No Impact on Kidney Fibrosis |
| Q89735579 | Inhibition of ISG15 Enhances the Anti-Cancer Effect of Trametinib in Colon Cancer Cells |
| Q37089986 | Inhibition of extracellular signal-regulated kinase signaling to prevent cardiomyopathy caused by mutation in the gene encoding A-type lamins. |
| Q37815135 | KRAS and BRAF: drug targets and predictive biomarkers |
| Q39860040 | KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer |
| Q36609858 | Ki67 expression levels are a better marker of reduced melanoma growth following MEK inhibitor treatment than phospho-ERK levels. |
| Q38107273 | Kinase Inhibitors of Marine Origin |
| Q40052283 | Long-term exposure of human renal carcinoma cells to PD98059 induces epithelial-mesenchymal transition-like phenotype and enhanced motility |
| Q34036341 | MEK and the inhibitors: from bench to bedside |
| Q38131383 | MEK inhibition in the treatment of advanced melanoma |
| Q36781119 | MEK inhibitor GSK1120212-mediated radiosensitization of pancreatic cancer cells involves inhibition of DNA double-strand break repair pathways |
| Q38092584 | MEK inhibitors as a chemotherapeutic intervention in multiple myeloma |
| Q39359514 | MEK inhibitors in oncology: a patent review (2015-Present). |
| Q39858584 | MEK inhibitors potentiate dexamethasone lethality in acute lymphoblastic leukemia cells through the pro-apoptotic molecule BIM. |
| Q47318847 | MEK inhibitors under development for treatment of non-small-cell lung cancer |
| Q35970072 | MEK inhibitors: a new class of chemotherapeutic agents with ocular toxicity |
| Q37872791 | MEK inhibitors: a patent review 2008 – 2010 |
| Q38591835 | MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road |
| Q35804449 | MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual Abl/Src inhibitor BMS-354/825 |
| Q33834171 | MEK2 is sufficient but not necessary for proliferation and anchorage-independent growth of SK-MEL-28 melanoma cells. |
| Q38180142 | Major therapeutic developments and current challenges in advanced melanoma |
| Q37605787 | Melanoma biomarkers: current status and utility in diagnosis, prognosis, and response to therapy |
| Q37301003 | Melanoma genetics and therapeutic approaches in the 21st century: moving from the benchside to the bedside |
| Q58882374 | Melanoma: targeting signaling pathways and RaLP |
| Q55354051 | Metabolic conversion of CI-1040 turns a cellular MEK-inhibitor into an antibacterial compound. |
| Q37149695 | Mitogen-activated protein kinase inhibition induces translocation of Bmf to promote apoptosis in melanoma. |
| Q36979035 | Mitogen-activated protein kinase kinase 1/2 inhibitors and 17-allylamino-17-demethoxygeldanamycin synergize to kill human gastrointestinal tumor cells in vitro via suppression of c-FLIP-s levels and activation of CD95. |
| Q38172165 | Mitogen-activated protein kinases and their role in radiation response |
| Q26824528 | Molecular landscape of pancreatic cancer: implications for current clinical trials |
| Q37778064 | Molecular targeted therapy for patients with melanoma: the promise of MAPK pathway inhibition and beyond |
| Q37483949 | Molecular-targeted therapy in malignant melanoma |
| Q38063115 | Monoclonal Antibodies and Other Targeted Therapies for Pancreatic Cancer |
| Q27852097 | Multicenter Phase I Trial of the Mitogen-Activated Protein Kinase 1/2 Inhibitor BAY 86-9766 in Patients with Advanced Cancer |
| Q38160836 | New and emerging treatment options for biliary tract cancer |
| Q36817127 | New approaches in metastatic melanoma: biological and molecular targeted therapies |
| Q24680988 | New molecularly targeted therapies for lung cancer |
| Q40076565 | New small-molecule inhibitors of mitogen-activated protein kinase kinase |
| Q36519041 | New therapies for hepatocellular carcinoma. |
| Q41869110 | New treatment approaches in melanoma: current research and clinical prospects |
| Q38245356 | No longer an untreatable disease: how targeted and immunotherapies have changed the management of melanoma patients |
| Q37828536 | Novel mitogen-activated protein kinase kinase inhibitors |
| Q37508041 | Novel therapeutics for melanoma |
| Q36812355 | Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies |
| Q38084846 | PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types |
| Q35227481 | PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling |
| Q38583246 | Pediatric cerebellar astrocytoma: a review. |
| Q37776547 | Personalized therapies in the cancer "omics" era |
| Q35096292 | Pharmacokinetics and pharmacodynamics of AZD6244 (ARRY-142886) in tumor-bearing nude mice |
| Q53569776 | Phase I and pharmacokinetics/pharmacodynamics study of the MEK inhibitor RO4987655 in Japanese patients with advanced solid tumors. |
| Q36929804 | Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor |
| Q38491964 | Pilot study of PD-0325901 in previously treated patients with advanced melanoma, breast cancer, and colon cancer |
| Q35639095 | Potential Pitfalls of Crossover and Thoughts on Iniparib in Triple-Negative Breast Cancer |
| Q54565907 | Preclinical assessment of novel BRAF inhibitors: integrating pharmacokinetic-pharmacodynamic modelling in the drug discovery process. |
| Q42909125 | Preclinical disposition and pharmacokinetics-pharmacodynamic modeling of biomarker response and tumour growth inhibition in xenograft mouse models of G-573, a MEK inhibitor |
| Q37733727 | Profiling of phospho-AKT, phospho-mTOR, phospho-MAPK and EGFR in non-small cell lung cancer. |
| Q38193520 | Prospects for MEK inhibitors for treating cancer. |
| Q42157466 | RAS signaling pathway mutations and hypertrophic cardiomyopathy: getting into and out of the thick of it. |
| Q37271795 | RAS: target for cancer therapy |
| Q39975996 | RNAi-mediated ERK2 knockdown inhibits growth of tumor cells in vitro and in vivo |
| Q24316181 | Raf family kinases: old dogs have learned new tricks |
| Q38075009 | Recent advances in cutaneous melanoma: towards a molecular model and targeted treatment. |
| Q46492805 | Reduction of chronic allograft nephropathy by inhibition of extracellular signal-regulated kinase 1 and 2 signaling |
| Q37822317 | Role of Ras/Raf/MEK/ERK signaling in physiological hematopoiesis and leukemia development |
| Q38241987 | Role of the MEK inhibitor trametinib in the treatment of metastatic melanoma |
| Q27851852 | Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial |
| Q38798084 | Selumetinib for the treatment of metastatic uveal melanoma: past and future perspectives |
| Q36471372 | Sensitivity of KRAS-Mutant Colorectal Cancers to Combination Therapy That Cotargets MEK and CDK4/6. |
| Q38747573 | Signaling pathways as therapeutic targets in biliary tract cancer. |
| Q33282750 | Simple, mammalian cell-based assay for identification of inhibitors of the Erk MAP kinase pathway |
| Q35583906 | Standard and emerging therapies for metastatic differentiated thyroid cancer |
| Q34057987 | Synergistic growth inhibition of anaplastic large cell lymphoma cells by combining cellular ALK gene silencing and a low dose of the kinase inhibitor U0126 |
| Q90357648 | Synergistic inhibition of MEK and reciprocal feedback networks for targeted intervention in malignancy |
| Q39063433 | Synthesis and biological evaluation of RGD-conjugated MEK1/2 kinase inhibitors for integrin-targeted cancer therapy |
| Q37920842 | Systemic treatment of metastatic melanoma: New approaches |
| Q37219806 | TEC and MAPK Kinase Signalling Pathways in T helper (TH) cell Development, TH2 Differentiation and Allergic Asthma |
| Q37710963 | Targeted cancer therapies in the twenty-first century: lessons from imatinib |
| Q33899923 | Targeted therapies for pancreatic cancer |
| Q38098888 | Targeting MAPK pathway in melanoma therapy |
| Q42020468 | Targeting Oncogenic BRAF in Human Cancer |
| Q38272894 | Targeting RAS-ERK signalling in cancer: promises and challenges |
| Q37629722 | Targeting mitogen-activated protein kinase kinase (MEK) in solid tumors |
| Q35859282 | Targeting mutant BRAF in melanoma: current status and future development of combination therapy strategies |
| Q38388217 | Targeting of MEK in lung cancer therapeutics |
| Q36804444 | Targeting signal transduction in pancreatic cancer treatment |
| Q40007423 | Targeting the Cellular Signaling: BRAF Inhibition and Beyond for the Treatment of Metastatic Malignant Melanoma |
| Q36486780 | Targeting the ERK signaling pathway in cancer therapy |
| Q38799845 | Targeting the KRAS Pathway in Non-Small Cell Lung Cancer |
| Q37745182 | Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail |
| Q36278239 | Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy |
| Q29618155 | Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer |
| Q38053855 | Targeting the Ras-ERK pathway in pancreatic adenocarcinoma. |
| Q39270291 | Targeting the Ras/Raf/MEK/ERK pathway in hepatocellular carcinoma |
| Q37753517 | Targeting the mitogen-activated protein kinase pathway: physiological feedback and drug response |
| Q37945533 | The "SWOT" of BRAF inhibition in melanoma: RAF inhibitors, MEK inhibitors or both? |
| Q36780645 | The Akt/mTOR and mitogen-activated protein kinase pathways in lung cancer therapy. |
| Q39560403 | The MEK inhibitor PD184352 enhances BMS-214662-induced apoptosis in CD34+ CML stem/progenitor cells |
| Q35835097 | The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models |
| Q37290440 | The RAS/mitogen activated protein (MAP) kinase pathway in melanoma biology and therapeutics |
| Q38270129 | The biology and clinical development of MEK inhibitors for cancer |
| Q38212717 | The clinical development of MEK inhibitors |
| Q35878248 | The current state of targeted therapy in melanoma: this time it's personal |
| Q90464791 | The effect of dual inhibition of Ras-MEK-ERK and GSK3β pathways on development of in vitro cultured rabbit embryos |
| Q38148745 | The intersection of immune-directed and molecularly targeted therapy in advanced melanoma: where we have been, are, and will be. |
| Q34494019 | The molecular targets for the diagnosis and treatment of pancreatic cancer |
| Q35140947 | The novel anti-MEK small molecule AZD6244 induces BIM-dependent and AKT-independent apoptosis in diffuse large B-cell lymphoma |
| Q37873464 | Therapy for metastatic melanoma: an overview and update |
| Q38071577 | Toward the Goal of Personalized Therapy in Pancreatic Cancer by Targeting the Molecular Phenotype |
| Q38083794 | Trametinib (GSK1120212) in the treatment of melanoma |
| Q38536713 | Trametinib in metastatic melanoma |
| Q50455744 | Transient MEK inhibitor-associated retinopathy in metastatic melanoma. |
| Q38386344 | Treatment of NRAS-mutant melanoma. |
| Q39982625 | Tumour-mediated disruption of dendritic cell function: inhibiting the MEK1/2-p44/42 axis restores IL-12 production and Th1-generation. |
| Q38199737 | Type III or allosteric kinase inhibitors for the treatment of non-small cell lung cancer |
| Q37538535 | Understanding melanoma signaling networks as the basis for molecular targeted therapy |
| Q37034487 | Understanding signaling cascades in melanoma |
| Q40154994 | Upstream signaling inhibition enhances rapamycin effect on growth of kidney cancer cells |
| Q53340770 | c-Jun N-terminal kinase is activated in non-small-cell lung cancer and promotes neoplastic transformation in human bronchial epithelial cells |
Search more.